Neuronal nicotinic acetylcholine receptor alpha-4-beta-2 and alpha-2-beta-2 (nAChR α4β2/α2β2)

The neuronal nicotinic acetylcholine receptors (nAChRs) α4β2 and α2β2 are heteromeric ligand-gated ion channels essential for cholinergic signaling in the central nervous system. The α4β2 subtype is the most abundant high-affinity nicotinic receptor in the brain, primarily located in the cortex, thalamus, and basal ganglia, where it modulates the release of neurotransmitters like dopamine and GABA (UniProt P43681, P17676). The α2β2 subtype is less widely distributed but plays a significant role in the interpeduncular nucleus and is involved in the regulation of nicotine's rewarding properties and cognitive processes (PMID: 25835595). These receptors are central to the pathology of nicotine dependence and are the primary targets for smoking cessation therapies such as varenicline and cytisine, which act as partial agonists to alleviate withdrawal while preventing nicotine-induced dopamine spikes (StatPearls). Beyond addiction, mutations in the subunits of these receptors, particularly CHRNA4 and CHRNB2, are associated with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) (UniProt). Furthermore, the decline of these receptors is linked to cognitive impairment in Alzheimer's and Parkinson's diseases, making them key targets for drug development aimed at cognitive enhancement and neuroprotection (PubMed).

Other names

alpha4beta2 nAChRalpha2beta2 nAChRCHRNA4/CHRNB2 receptorCHRNA2/CHRNB2 receptorNicotinic acetylcholine receptor alpha-4 subunitNicotinic acetylcholine receptor alpha-2 subunitNicotinic acetylcholine receptor beta-2 subunitNeuronal acetylcholine receptor subunit alpha-4Neuronal acetylcholine receptor subunit alpha-2Neuronal acetylcholine receptor subunit beta-2

Drugs targeting these receptors primarily act as partial agonists, full agonists, or antagonists. Partial agonists like varenicline bind to the α4β2 receptor to trigger a moderate release of dopamine, which helps alleviate withdrawal symptoms, while simultaneously blocking nicotine from binding and exerting its full rewarding effect (StatPearls). Other compounds may act as positive allosteric modulators (PAMs) to enhance endogenous cholinergic signaling, which is beneficial for treating cognitive deficits (PubMed).